Here are three ASX 200 shares with major upside potential…
The post 3 ASX 200 shares with major upside potential in 2022 appeared first on The Motley Fool Australia. –
If you’re interested in adding some S&P/ASX 200 Index (ASX: XJO) shares to your portfolio this month, then the three listed below could be worth considering.
These three ASX 200 shares have been named as buys and tipped to generate strong returns for investors. They are as follows:
Aristocrat Leisure Limited (ASX: ALL)
The first ASX 200 share to look at is Aristocrat Leisure. It is a gaming technology company with a leading portfolio of poker machines and digital games. The latter includes gambling and non-gambling games such as RAID. The company has also just announced a deal to acquire London-listed leading global online gambling software and content supplier, Playtech, for $5 billion. All in all, this has analysts tipping Aristocrat to grow its earnings at a strong rate over the medium term
Morgans is positive on the company. It currently has an add rating and $52.50 price target on its shares. This compares to the most recent Aristocrat share price of $42.58.
NEXTDC Ltd (ASX: NXT)
Another ASX 200 share to look at is NEXTDC. It is a leading data centre operator with a collection of world class centres across key locations throughout Australia. Combined with its potential expansion into Asia and Edge data centres and the structural shift to the cloud, NEXTDC appears well-placed for growth over the 2020s.
Citi is a fan and currently has a buy rating and $15.40 price target on NEXTDC’s shares. This compares to the latest NEXTDC share price of $12.25.
ResMed Inc. (ASX: RMD)
A final ASX 200 share that has been tipped to generate strong returns for investors is ResMed. It is a medical device company with a world class portfolio of products in the massive sleep treatment market. It has been tipped to grow strongly over the long term due to its leadership position, growing demand, and its patient-centric, connected-care digital platform. The latter is addressing the main pinch points across the healthcare value chain.
Credit Suisse is bullish on ResMed. So much so, it has an outperform rating and $43.00 price target on the company’s shares. This compares favourably to the latest ResMed share price of $35.56.
The post 3 ASX 200 shares with major upside potential in 2022 appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of August 16th 2021
Motley Fool contributor James Mickleboro owns NEXTDC Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.